EntryPoint Capital LLC Buys New Position in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• EntryPoint Capital LLC purchased a new stake in Supernus Pharmaceuticals, acquiring 12,412 shares valued at approximately $406,000 in the first quarter.
• Supernus Pharmaceuticals' stock has a market capitalization of $2.39 billion and is currently trading around $42.68, with analysts giving it a consensus rating of "Moderate Buy."
• Insider trading included substantial sales by directors, with a total of 152,826 shares sold recently, indicating a shift in ownership among company insiders.

EntryPoint Capital LLC bought a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the first quarter, according to the company in its most recent filing with the SEC. The fund bought 12,412 shares of the specialty pharmaceutical company's stock, valued at approximately $406,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Raiffeisen Bank International AG bought a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $25,000. Financial Management Professionals Inc. bought a new stake in shares of Supernus Pharmaceuticals during the 1st quarter worth approximately $30,000. Versant Capital Management Inc lifted its stake in shares of Supernus Pharmaceuticals by 6,931.3% during the 1st quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock worth $37,000 after acquiring an additional 1,109 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Supernus Pharmaceuticals during the 1st quarter worth approximately $41,000. Finally, GF Fund Management CO. LTD. bought a new stake in shares of Supernus Pharmaceuticals during the 4th quarter worth approximately $42,000.

Insider Activity

In other news, Director Bethany Sensenig sold 5,369 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, August 14th. The stock was sold at an average price of $42.25, for a total value of $226,840.25. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Jack A. Khattar sold 140,000 shares of the company's stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $42.02, for a total value of $5,882,800.00. Following the transaction, the chief executive officer directly owned 1,030,183 shares in the company, valued at $43,288,289.66. This represents a 11.96% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 152,826 shares of company stock worth $6,424,773. 8.80% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Wall Street Zen raised Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Cantor Fitzgerald raised their price target on Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a research note on Wednesday, August 6th. Finally, Zacks Research raised Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 19th. Two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $41.00.

Supernus Pharmaceuticals Trading Up 0.1%

Shares of NASDAQ:SUPN traded up $0.03 on Tuesday, reaching $44.46. The company had a trading volume of 91,892 shares, compared to its average volume of 639,285. Supernus Pharmaceuticals, Inc. has a 52-week low of $29.16 and a 52-week high of $45.60. The firm's 50 day simple moving average is $35.64 and its 200-day simple moving average is $33.69. The firm has a market capitalization of $2.49 billion, a PE ratio of 38.60 and a beta of 0.74.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.